Off‐label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: a retrospective study
Identifieur interne : 001367 ( Main/Exploration ); précédent : 001366; suivant : 001368Off‐label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: a retrospective study
Auteurs : A. Klein [Allemagne] ; B. Coras [Allemagne] ; M. Landthaler [Allemagne] ; P. Babilas [Allemagne]Source :
- Journal of the European Academy of Dermatology and Venereology [ 0926-9959 ] ; 2012-11.
Abstract
Background Fumarates are approved for the systemic treatment of moderate and severe psoriasis vulgaris in Germany. However, a number of studies and case reports indicate their efficacy in the treatment of further inflammatory skin disorders or granulomatous skin diseases. Objectives To examine the efficacy and safety of fumarates for the treatment of granulomatous and inflammatory skin diseases other than psoriasis vulgaris. Patients and methods The therapeutic efficacy and side‐effects of fumarate therapy were analysed retrospectively in patients with granuloma annulare (GA, n = 4), cutaneous sarcoidosis (SA, n = 1), lichen planus (LP, n = 3), pityriasis rubra pilaris (PRP, n = 1) or chronic discoid lupus erythematosus (CDLE, n = 1). Results Six patients (GA: 3/4; LP: 2/3; PRP: 1/1) showed complete clearance and two patients (GA: 1/3; SA: 1/1) had a partial response, and the CDLE patient showed stable disease under a combination therapy with hydroxychloroquine. Side‐effects associated with fumarate therapy were seen in seven of ten patients and resolved spontaneously upon dose reduction or discontinuation of the therapy. Conclusion According to this data, fumarates may represent a new approach in the treatment of granulomatous and inflammatory skin diseases other than psoriasis vulgaris. For the first time, the successful treatment of LP and CDLE with fumarates is reported. Side‐effects are not limiting in most cases, but can hamper a dose escalation.
Url:
DOI: 10.1111/j.1468-3083.2011.04303.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000240
- to stream Istex, to step Curation: 000240
- to stream Istex, to step Checkpoint: 000376
- to stream Main, to step Merge: 001368
- to stream Main, to step Curation: 001367
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Off‐label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: a retrospective study</title><author><name sortKey="Klein, A" sort="Klein, A" uniqKey="Klein A" first="A." last="Klein">A. Klein</name></author><author><name sortKey="Coras, B" sort="Coras, B" uniqKey="Coras B" first="B." last="Coras">B. Coras</name></author><author><name sortKey="Landthaler, M" sort="Landthaler, M" uniqKey="Landthaler M" first="M." last="Landthaler">M. Landthaler</name></author><author><name sortKey="Babilas, P" sort="Babilas, P" uniqKey="Babilas P" first="P." last="Babilas">P. Babilas</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:63ED1538E15DDAAA22B18CC0A617519D00E6AFF9</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1468-3083.2011.04303.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-Z8L444H5-V/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000240</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000240</idno><idno type="wicri:Area/Istex/Curation">000240</idno><idno type="wicri:Area/Istex/Checkpoint">000376</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000376</idno><idno type="wicri:doubleKey">0926-9959:2012:Klein A:off:label:use</idno><idno type="wicri:Area/Main/Merge">001368</idno><idno type="wicri:Area/Main/Curation">001367</idno><idno type="wicri:Area/Main/Exploration">001367</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Off‐label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: a retrospective study</title><author><name sortKey="Klein, A" sort="Klein, A" uniqKey="Klein A" first="A." last="Klein">A. Klein</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Regensburg, Regensburg</wicri:regionArea><wicri:noRegion>Regensburg</wicri:noRegion><wicri:noRegion>Regensburg</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation></author><author><name sortKey="Coras, B" sort="Coras, B" uniqKey="Coras B" first="B." last="Coras">B. Coras</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, Klinikum München‐Schwabing, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Landthaler, M" sort="Landthaler, M" uniqKey="Landthaler M" first="M." last="Landthaler">M. Landthaler</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Regensburg, Regensburg</wicri:regionArea><wicri:noRegion>Regensburg</wicri:noRegion><wicri:noRegion>Regensburg</wicri:noRegion></affiliation></author><author><name sortKey="Babilas, P" sort="Babilas, P" uniqKey="Babilas P" first="P." last="Babilas">P. Babilas</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Regensburg, Regensburg</wicri:regionArea><wicri:noRegion>Regensburg</wicri:noRegion><wicri:noRegion>Regensburg</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of the European Academy of Dermatology and Venereology</title><title level="j" type="alt">JOURNAL OF EUROPEAN ACADEMY DERMATOLOGY VENEREOLOGY</title><idno type="ISSN">0926-9959</idno><idno type="eISSN">1468-3083</idno><imprint><biblScope unit="vol">26</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1400">1400</biblScope><biblScope unit="page" to="1406">1406</biblScope><biblScope unit="page-count">7</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2012-11">2012-11</date></imprint><idno type="ISSN">0926-9959</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0926-9959</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background Fumarates are approved for the systemic treatment of moderate and severe psoriasis vulgaris in Germany. However, a number of studies and case reports indicate their efficacy in the treatment of further inflammatory skin disorders or granulomatous skin diseases. Objectives To examine the efficacy and safety of fumarates for the treatment of granulomatous and inflammatory skin diseases other than psoriasis vulgaris. Patients and methods The therapeutic efficacy and side‐effects of fumarate therapy were analysed retrospectively in patients with granuloma annulare (GA, n = 4), cutaneous sarcoidosis (SA, n = 1), lichen planus (LP, n = 3), pityriasis rubra pilaris (PRP, n = 1) or chronic discoid lupus erythematosus (CDLE, n = 1). Results Six patients (GA: 3/4; LP: 2/3; PRP: 1/1) showed complete clearance and two patients (GA: 1/3; SA: 1/1) had a partial response, and the CDLE patient showed stable disease under a combination therapy with hydroxychloroquine. Side‐effects associated with fumarate therapy were seen in seven of ten patients and resolved spontaneously upon dose reduction or discontinuation of the therapy. Conclusion According to this data, fumarates may represent a new approach in the treatment of granulomatous and inflammatory skin diseases other than psoriasis vulgaris. For the first time, the successful treatment of LP and CDLE with fumarates is reported. Side‐effects are not limiting in most cases, but can hamper a dose escalation.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li></region><settlement><li>Munich</li></settlement></list><tree><country name="Allemagne"><noRegion><name sortKey="Klein, A" sort="Klein, A" uniqKey="Klein A" first="A." last="Klein">A. Klein</name></noRegion><name sortKey="Babilas, P" sort="Babilas, P" uniqKey="Babilas P" first="P." last="Babilas">P. Babilas</name><name sortKey="Coras, B" sort="Coras, B" uniqKey="Coras B" first="B." last="Coras">B. Coras</name><name sortKey="Klein, A" sort="Klein, A" uniqKey="Klein A" first="A." last="Klein">A. Klein</name><name sortKey="Landthaler, M" sort="Landthaler, M" uniqKey="Landthaler M" first="M." last="Landthaler">M. Landthaler</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001367 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001367 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:63ED1538E15DDAAA22B18CC0A617519D00E6AFF9
|texte= Off‐label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: a retrospective study
}}
| This area was generated with Dilib version V0.6.33. |  |